In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't usability alone—it's making it easier for patients and sites to interact more effectively with each other.
|Articles|June 18, 2006
- Applied Clinical Trials-06-19-2006
- Volume 0
- Issue 0
Omnicomm Systems Inc., Introduces New TrialMaster V.4.0 at DIA's 42nd Annual Meeting
TrialMaster V.4.0. is a flexible, painless, and affordable eClinical Solution.
Advertisement
Philadelphia, June 18–20, Booth # 1144- OmniComm Systems, Inc., one of the fastest growing companies in the EDC marketplace, announced today the launch of TrialMaster™ Version 4.0 eClinical trial solution.
TrialMaster™ Version 4.0 includes:
- eData Capture functionality
- Data Management functionality
- Trial Management functionality
- Easy Trial Build capability
Articles in this issue
over 20 years ago
BBK Healthcare, Inc. Evolves to Become BBK Worldwideover 20 years ago
Datafarm Announces the Release of Web-Based eCTD ViewerAdvertisement
Related to this article
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, shares what she expects to be at the center of the conversation—from building trust between patients and sites to where AI may and may not have a role in that relationship.
A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Why clinical development’s next AI bottleneck is not the model, but the system around it.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
How a Platform Approach Can Scale AI’s Impact in Life Sciences
2
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
3
Operationalizing the Patient Voice: Converging U.S., EU, and UK Requirements and the Role of Real-World Patient-Reported Data
4
Lessons from Hundreds of Clinical Trials: AI’s Successes, Gaps, and Opportunities
5